<DOC>
	<DOCNO>NCT02040311</DOCNO>
	<brief_summary>The purpose study determine efficacy safety topiramate ( 96 mg 192 mg daily ) compare placebo maintain weight loss obese subject participate eight week intensive non-pharmacologic weight loss program . The primary efficacy endpoint percent change body weight enrollment visit week 60 .</brief_summary>
	<brief_title>Topiramate : Long-Term Maintenance Weight Loss Induced Low-Calorie Diet Obese Subjects</brief_title>
	<detailed_description>The study randomize , double-blind , placebo-controlled , parallel-group , multicenter trial . It originally design last total 74 week : 8 week non.pharmacologic low-calorie ( 800 1000 kcl/d ) weight loss run-in phase , 8 week titration phase , 52 week maintenance phase , 6 week drug taper follow phase .</detailed_description>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Read sign informed consent form nature study fully explain 18 75 year og age enrollment subject must either : 1 . A body mass index BMI ≥ 33 kg/m*m &lt; 50 kg/m*m , 2 . A BMI ≥ 30 kg/m*m &lt; 50 kg/m*m follow establish comorbidities present : Controlled hypertension dyslipidemia . Antihypertensive hypolipidemic medication stable dose least two month prior enrollment . If subject clinically diagnose condition result enrollment assessment , continue enrollment phase clinical judgment investigator initiation antihypertensive hypolipidemic therapy require . Subjects diagnose type 2 diabetes mean OGTT enrollment visit require anti diabetic therapy accord clinical judgement investigator . Stable weight ( vary 3 kg ) least 3 month prior enrollment . Female subject must post menopausal least year surgically incapable childbearing , practice abstinence acceptable method birth control . If female subject child bear potential practicing acceptable method birth control , must negative urine pregnancy test enrollment , well baseline , prior receive study drug . Randomization criteria 1 . Weight reduction of≥ 8 % enrollment body weight randomization visit ; 2 . Subjects must either : 2a ) A BMI ≥ 30 kg/m*m &lt; 50 kg/m*m , 2b ) A BMI ≥ 27 kg/m*m &lt; 50 kg/m*m follow establish comorbidities present : control hypertension dyslipidemia . Subjects meet follow criterion exclude participate study . Prior exposure know contraindication hypersensitivity topiramate ; Exposure experimental drug device within 30 day prior enrollment ; Pregnancy nursing subject plan become pregnant study ; An establish diagnosis diabetes prior study enrollment ; History evidence clinically significant hepatic disease ; Evidence renal impairment ; Significant cardiovascular disease ; Uncontrolled hypertension 180 / 100 mmHg Hypertensive subject medication must dose hypertensive medication least 2 month ; Uncontrolled thyroid disease include hyper hypothyroidism abnormal TSHlevel ; A history obesity know cause e.g . Cushings disease ; A history family history ( first degree relative ) kidney stone ; Previous gastric restrictive surgery surgical procedure cause weight loss , include liposuction ; History gluten nongluten induce enteropathy ; Clinically significant lactose intolerance , opinion investigator ; Malignancy history malignancy within 5 year prior enrollment , basal cell carcinoma skin ; History og seizures significant CNS disorder ; History significant psychiatric disorder include schizophrenia , psychosis major affective disorder ; History anorexia nervosa , bulimia og binge eat disorder ; A significant change smoking habit within 2 month enrollment visit , opinion investigator ; History drug alcohol abuse within previous 2 year ; Positive result urine drug screen enrollment ; Use weight loss preparation within 30 day prior enrollment ; Use systemic corticosteroid within 30 day prior enrollment ; Clinically significant hematological immunological disorder ; Currently receive psychotropic medication , except episodic use certain medication ; Receiving exclude medication , depend episodic chronic use ; Any significant condition , opinion investigator , could interfere subject participation compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>